Effects of Fenofibrate on Adipocytokine Levels In Hypertriglyceridemic Patients
- Registration Number
- NCT00745407
- Lead Sponsor
- Gachon University Gil Medical Center
- Brief Summary
Fenofibrate increases adiponectin levels, but reduces leptin levels
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- hypertriglyceridemia
Exclusion Criteria
- chronic liver disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description fenofibrate 160 mg, placebo fenofibrate -
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain fenofibrate's effects on adipocytokines in hypertriglyceridemia?
How does fenofibrate compare to other fibrates in modulating adiponectin and leptin levels?
Are specific adipocytokine biomarkers predictive of fenofibrate response in hypertriglyceridemic patients?
What adverse events are associated with fenofibrate in long-term hypertriglyceridemia treatment?
How do fenofibrate's adipocytokine effects relate to its role in lipid metabolism and cardiovascular risk reduction?
Trial Locations
- Locations (1)
Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Gil Medical Center🇰🇷Incheon, Korea, Republic of